Experimental drug shows promise in delaying early-onset Alzheimer’s

Table of Contents

Study suggests anti-amyloid treatment may halve risk of cognitive decline in genetically predisposed individuals.

An experimental drug has demonstrated potential in reducing the risk of Alzheimer’s disease among individuals genetically predisposed – or “destined” – to develop the condition in their 30s, 40s or 50s. This finding emerges from a study conducted by the Knight Family Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU) at Washington University School of Medicine in St Louis. The research indicates that early intervention to eliminate amyloid plaques from the brain, many years before symptoms arise, can delay the onset of Alzheimer’s dementia [1].

The international study encompassed 73 participants carrying rare, inherited genetic mutations that lead to the overproduction of amyloid in the brain, virtually ensuring the development of Alzheimer’s disease in middle age. Among a subgroup of 22 participants who exhibited no cognitive impairments at the study’s outset and who received the drug for an average of eight years, the treatment reduced the risk of developing symptoms from nearly 100% to approximately 50% [1].

Longevity.Technology: This study could mark a pivotal advancement in preventive neurology. By targeting amyloid plaques well before cognitive decline manifests, this approach highlights the potential of proactive interventions in altering the disease’s trajectory. Notably, participants who received the treatment for an average of eight years experienced a whopping 50% reduction in the risk of developing dementia, highlighting the significance of early and sustained therapeutic strategies. Given the massive global burden of Alzheimer’s – currently affecting over 55 million people worldwide and projected to triple by 2050 – such a reduction in risk could translate into profound public health benefits [2]. Delaying or preventing dementia not only preserves cognitive function and independence for individuals but also alleviates the enormous economic and emotional toll on families, caregivers and healthcare systems. If refined and expanded to more common forms of Alzheimer’s, this preventive approach could reshape aging and longevity medicine, shifting the focus from managing decline to actively preserving brain health.

However, while these findings are promising, they primarily pertain to individuals with rare genetic mutations leading to early-onset Alzheimer’s. Extrapolating these results to the broader population requires caution, as the majority of Alzheimer’s cases are sporadic and influenced by a complex interplay of genetic and environmental factors. Additionally, the safety profile of long-term anti-amyloid therapy necessitates thorough evaluation, given potential adverse effects such as amyloid-related imaging abnormalities. Future research should focus on validating these outcomes in more diverse cohorts and establishing optimal treatment protocols to maximize benefits while minimizing risks.

Therapeutic implications

The drug under investigation, gantenerumab, is an anti-amyloid antibody designed to target and clear amyloid plaques – a hallmark of Alzheimer’s pathology – from the brain. The study’s findings lend support to the amyloid hypothesis, which posits that the accumulation of amyloid plaques plays a pivotal role in the progression of Alzheimer’s disease. (While some researchers argue that reducing amyloid plaques can slow disease progression, others question whether amyloid is the central cause or merely a byproduct of neurodegeneration, and there has been much debate surrounding the validity of the amyloid hypothesis).By administering gantenerumab well before the onset of symptoms, researchers aimed to assess its efficacy in delaying or preventing cognitive decline [1].

Senior author Randall J Bateman, MD, the Charles F and Joanne Knight Distinguished Professor of Neurology at Washington University, was clear about the significance of the study: “Everyone in this study was destined to develop Alzheimer’s disease and some of them haven’t yet,” he said. “We don’t yet know how long they will remain symptom-free – maybe a few years or maybe decades. In order to give them the best opportunity to stay cognitively normal, we have continued treatment with another anti-amyloid antibody in hopes they will never develop symptoms at all. What we do know is that it’s possible at least to delay the onset of the symptoms of Alzheimer’s disease and give people more years of healthy life [3].”

Maria C Carrillo, PhD, chief science officer and medical affairs lead at the Alzheimer’s Association, also expressed optimism regarding the preliminary results. “These exciting preliminary findings hint very clearly at the potential role of lowering beta amyloid in prevention of Alzheimer’s disease,” she said. “The Alzheimer’s Association looks forward with great anticipation to replication, extension and expansion of this genuinely unprecedented and groundbreaking research, and we have made a significant investment in ensuring these important scientific questions can be investigated. Discoveries like this convincingly illustrate why it is so important for research into Alzheimer’s and all diseases that cause dementia to continue, expand and accelerate [3].”

Implications for late-onset Alzheimer’s prevention

The study’s outcomes may have broader implications for the prevention of late-onset Alzheimer’s disease, which typically manifests in individuals aged 60 and above. Bateman highlighted this potential: “If late-onset Alzheimer’s prevention trials have similar results to the DIAN-TU trials, there soon could be Alzheimer’s preventions available for the general population. I am highly optimistic now, as this could be the first clinical evidence of what will become preventions for people at risk for Alzheimer’s disease. One day soon, we may be delaying the onset of Alzheimer’s disease for millions [3].”

While gantenerumab is no longer in production, the study highlights the potential of anti-amyloid therapies in altering the course of Alzheimer’s disease. Ongoing research into similar treatments, such as lecanemab and donanemab, continues to explore their efficacy in both early-onset and late-onset Alzheimer’s populations. These investigations aim to determine whether early intervention with anti-amyloid antibodies can provide sustained cognitive benefits and delay disease progression, and by targeting amyloid accumulation early, there is potential to extend the period of cognitive health and improve quality of life. Continued research and clinical trials are essential to validate these results and expand their applicability to broader populations at risk for Alzheimer’s disease.